← Back to Mankind Pharma Ltd. overview
Mankind Pharma Ltd. — 10-Year Financials
Annual P&L, balance sheet, and key ratios from public BSE/NSE filings.
| Period | Revenue | Net Profit | EPS (₹) | Total Assets | Shareholder Equity | ROE (%) | ROCE (%) | D/E | Net Margin (%) |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹12,207 cr | ₹1,991 cr | ₹49.2 | ₹27,760 cr | ₹14,332 cr | 13.89% | 12.86% | 0.59x | 16.31% |
| FY2024 | ₹10,259 cr | ₹1,913 cr | ₹47.68 | ₹11,963 cr | ₹9,363 cr | 20.43% | 25.35% | 0.02x | 18.65% |
| FY2023 | ₹8,749 cr | ₹1,282 cr | ₹32 | ₹9,715 cr | ₹7,435 cr | 17.24% | 22.5% | 0.02x | 14.65% |
| FY2022 | ₹7,782 cr | ₹1,433 cr | ₹35.78 | ₹9,148 cr | ₹6,155 cr | 23.29% | 28.89% | 0.14x | 18.42% |
Revenue: Total income from operations (₹ crore).
EPS: Earnings per share (₹), basic.
ROE: Net profit / average shareholder equity.
ROCE: EBIT / capital employed.
D/E: Total debt / shareholder equity.
Net Margin: Net profit as a % of revenue.
All figures sourced from public BSE/NSE filings. Ratios are pre-computed estimates and may differ from primary filings due to rounding.
Educational content — not investment adviceAll financial data is sourced from public filings and shown here for educational purposes only. EquitiesIndia.com is not a SEBI-registered Investment Adviser or Research Analyst. Nothing on this page constitutes a recommendation or solicitation to transact in any security. All data is at least 90 days old. Past performance is not indicative of future results.